Sanofi and Selecta Biosciences have entered into a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies. The collaboration will leverage Selecta’s Synthetic Vaccine Particle (SVP) platform to engineer nanoparticles with the ideal structure and composition to produce immune tolerance by balancing the overactive response to specific allergy-causing antigens.   Sanofi has an exclusive license to develop an immunotherapy designed...